Scalper1 News
Biotech Receptos (RCPT) reported positive midstage trial results for its lead drug candidate for ulcerative colitis Thursday, sending the stock up as much as 7% in early trading. Receptos said that the phase-two study, called Touchstone, met all six of its primary endpoints for improving the chronic bowel disease after 32 weeks of maintenance with ozanimod, formerly known as RPC1063. Ozanimod first made a splash last September with its midstage Scalper1 News
Scalper1 News